Navigation Links
Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
Date:6/25/2010

(this,'o','ExternalLink');" target='_blank' href="http://www.Vpriv.com">http://www.Vpriv.com.

Important Safety Information

The most serious adverse reactions in patients treated with VPRIV were hypersensitivity reactions.

Infusion-related reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of infusion-related reactions were: headache, dizziness, hypotension, hypertension, nausea, fatigue/asthenia, and pyrexia. Generally the infusion-related reactions were mild and, in treatment-naive patients, onset occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. Other commonly observed adverse reactions in [greater than or equal to]10% of patients were: abdominal pain, back pain, joint pain, upper respiratory tract infection, and activated partial thromboplastin time prolonged. Adverse reactions more commonly seen in pediatric patients (>10% difference) included upper respiratory tract infection, rash, activated partial thromboplastin time prolonged, and pyrexia.

In clinical trials one patient developed neutralizing antibodies.

About Gaucher Disease

Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. This enzymatic deficiency causes an accumulation of glucocerebroside, primarily in macrophages. In this lysosomal storage disorder, clinical features are reflective of the distribution of Gaucher cells in the liver, spleen, bone marrow, and other organs. The accumulation of glucocerebroside in the liver and spleen leads to organomegaly. Presence of Gaucher cells in the bone marrow and spleen lead to cl
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire plc Appoints Two New Board Directors
2. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
3. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
4. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
5. Shires Replenished Portfolio Drives Excellent Quarterly Performance
6. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
7. Shire Supports Rare Disease Day 2010
8. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
9. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
10. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
11. New Shire Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Invetech , a ... automation, and contract manufacturing, and  NanoCellect Biomedical, ... and cell sorting technology for life science researchers, ... flow cytometry platform. Headquartered in ... developed a microchip-based cell sorting technology. NanoCellect,s flow ...
(Date:4/21/2015)... 21, 2015  scPharmaceuticals, Inc., a privately ... for subcutaneous delivery, announced today that it ... investigational proprietary drug product, Furosemide Injection Solution, ... congestive heart failure. Concurrently with ... proprietary patch pump.  The patch pump is ...
(Date:4/21/2015)... (UK) (PRWEB) April 21, 2015 ... and its clinical applications will be presented ... include engineers, scientists, regulators and clinicians from ... meeting is sponsored by Invibio Biomaterial Solutions. ... biomaterials, a specialist in manufacturing and R&D ...
(Date:4/20/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and ... and commercializing proven cancer therapies in new orphan ... the 106th Annual Meeting of the American ... on the potential for its lead product candidate ...
Breaking Biology Technology:NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 32nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5
... Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... CSKI ), a,leading fully integrated pharmaceutical company ... ("PRC"), announced today that it,has successfully completed the ... certification, or CE mark, which indicates that,a company,s ...
... seven medical,experts in psychiatry from across the world ... action to optimize services for people with a,diagnosis ... bipolar,disorder(i)., Professor W. Wolfgang Fleischhacker, principal author ... Disorders: Clinical,Policy, and Research Challenges which was published ...
... MedNet Solutions, a global,eClinical technology company specializing ... active involvement as a speaker,sponsor and exhibitor at ... Conference, to be held Sunday, September 21 through,Wednesday, ... has invited Dr. Timothy Pratt, PhD, Chief Marketing ...
Cached Biology Technology:China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 2China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 3Global Psychiatrists Unite to Improve Services in Mental Health 2Global Psychiatrists Unite to Improve Services in Mental Health 3MedNet Solutions to Speak, Sponsor and Exhibit at the 2008 Society of Clinical Data Management Annual Conference in Dallas 2
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... to double the odds a teenage girl will begin smoking, ... who analyzed the dieting and smoking practices of 8,000 adolescents, ... also less likely than girls to diet, according to findings ... Dieting was a significant predictor of initiation of regular smoking ...
... 2007- As of late, many uncertainties have been sprouting ... wondering if precision agricultural technologies can improve crop yield ... asking a number of questions from, which hybrid should ... applying nitrogen fertilizer at a uniform rate produce a ...
... Chicago researchers have identified new sites on the ... delivered to treat infections. "The primary challenge ... by the pathogens which became resistant to antibiotics," ... UIC,s Center for Pharmaceutical Biotechnology and lead investigator ...
Cached Biology News:Girls who begin dieting twice as likely to start smoking 2Girls who begin dieting twice as likely to start smoking 3The 5 Ws of corn production 2UIC researchers find promising new targets for antibiotics 2
... Blot Processing Standard Tray (3 per ... gel staining and blot processing.Automated staining ... for proteins and nucleic acid analysis.Prepares ... and chromogenic detection.Programmable control of protocol, ...
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
Biology Products: